You have 1 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Interferon beta-1a

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial in Cairo (Blood sample collection)

Recruiting
  • Multiple Sclerosis
  • Blood sample collection
  • Cairo, Egypt
    Nasser Institute for Research and Treatment
Feb 21, 2023

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial

Not yet recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +5 more
  • Interferon Beta-1A
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2023

Multiple Sclerosis Trial in Shreveport (Interferon beta 1a, oral doxycycline)

Completed
Has Results
  • Multiple Sclerosis
  • Interferon beta 1a, oral doxycycline
  • Shreveport, Louisiana
    LSU Health Sciences Center Shreveport
Oct 11, 2022

Covid19 Trial in United States (IFN beta-1a, Dexamethasone)

Terminated
Has Results
  • Covid19
  • Aurora, Colorado
  • +3 more
Oct 13, 2022

Healthy Subjects, Pharmacokinetics, Pharmacodynamics Trial in West Bend (Interferon beta-1a, Peginterferon beta-1a, Placebo)

Completed
  • Healthy Subjects
  • +2 more
  • Interferon beta-1a
  • +2 more
  • West Bend, Wisconsin
    Spaulding Clinical Research
Aug 16, 2021

Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis (RRMS)
  • Pegylated interferon beta-1a
  • Interferon Beta-1A Prefilled Syringe
  • Tehran, Iran, Islamic Republic of
    Sina Hospital
Feb 5, 2022

Female Participants Exposed to Subcutaneous Peginterferon

Completed
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Interferon Beta Therapy
  • Göttingen, Germany
    Research Site
Nov 1, 2021

Multiple Sclerosis Trial (Diroximel Fumarate, Avonex, Tysabri)

Not yet recruiting
  • Multiple Sclerosis
  • Diroximel Fumarate
  • +3 more
  • (no location specified)
Dec 12, 2022

Learn About Interferon-beta Exposure of Pregnant Women During

Not yet recruiting
  • Multiple Sclerosis (MS)
  • Avonex (IFNβ-1-a, Biogen Netherlands B.V)
  • +5 more
  • Multiple Locations, Finland
  • +1 more
Sep 19, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in Nizhny Novgorod (BCD-054 180 mcg, Avonex®, BCD-054 240 mcg)

Completed
  • Multiple Sclerosis, Relapsing-Remitting
  • BCD-054 180 mcg
  • +3 more
  • Nizhny Novgorod, Russian Federation
    State Budgetary Healthcare Institution of Nizhny Novgorod region
Sep 6, 2021

Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
  • Multiple Sclerosis
  • Diroximel Fumarate
  • +8 more
  • Eden Prairie, Minnesota
    OptumInsight
Jan 9, 2023

Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

Terminated
Has Results
  • Relapsing-remitting Multiple Sclerosis
  • Rockland, Massachusetts
  • +1 more
Jul 13, 2021

Multiple Sclerosis, Relapsing-Remitting Trial in Kocaeli (EK-12, INF beta-1a)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Kocaeli, Turkey
    Kocaeli University, Faculty of Medicine, Department of Neurology
Jul 23, 2021

Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

Terminated
Has Results
  • Relapsing-remitting Multiple Sclerosis
  • Rockland, Massachusetts
  • +1 more
Jul 13, 2021

Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Completed
  • Relapsing Multiple Sclerosis (RMS)
  • Rebif (Interferon beta-1a)
  • Alger, Algeria
  • +40 more
Mar 22, 2022

Preventive Medicine, Multi Organ Failure Trial in Estonia, Finland, Lithuania (Interferon Beta-1A, Placebo)

Terminated
Has Results
  • Preventive Medicine
  • Multi Organ Failure
  • Interferon Beta-1A
  • Placebo
  • Tartu, Estonia
  • +8 more
Dec 22, 2020

Relapsing Multiple Sclerosis Trial in Worldwide (Interferon beta-1a, Ocrelizumab-matching , Ocrelizumab)

Active, not recruiting
Has Results
  • Relapsing Multiple Sclerosis
  • Interferon beta-1a
  • +3 more
  • Phoenix, Arizona
  • +140 more
Jan 2, 2023

Interferon Beta-1a on Changes of Non-conventional MRI Measures

Completed
  • Multiple Sclerosis
  • Avonex® monotherapy (6.0 MIU administered i.m. each week)
  • Buffalo, New York
    The Jacobs Neurological Institute
Dec 23, 2020

Covid19 Trial in Kingston (Remdesivir, Acalabrutinib, Interferon beta-1a)

Not yet recruiting
  • Covid19
  • Kingston, Jamaica
    Univeristy of the West Indies
May 10, 2021

COPD (COPD) Trial in Manchester, Nottingham, Southampton (Interferon Beta-1A, Placebo)

Completed
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Interferon Beta-1A
  • Placebo
  • Belfast, United Kingdom
  • +15 more
Jan 3, 2023

Multiple Sclerosis Trial in Worldwide (Interferon beta-1a, Fingolimod, Placebo capsule)

Recruiting
Has Results
  • Multiple Sclerosis
  • Interferon beta-1a
  • +3 more
  • Birmingham, Alabama
  • +106 more
Jan 13, 2023

SARS-CoV Infection, Interferon, Covid19 Trial in Santiago (Peginterferon beta-1a)

Completed
  • SARS-CoV Infection
  • +2 more
  • Peginterferon beta-1a
  • Santiago, Chile
    Pontificia Universidad Católica de Chile
Sep 2, 2021

COVID-19 Trial in Tehran (Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A)

Completed
  • COVID-19
  • Tehran, Iran, Islamic Republic of
    Loghman Hakim Hospital, Shahid Beheshti University of Medical Sc
May 2, 2020

Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7 Trial in Seattle (drug, other, biological, radiation)

Terminated
Has Results
  • Merkel Cell Polyomavirus Infection
  • Stage IV Merkel Cell Carcinoma AJCC v7
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Feb 25, 2022

Relapsing Multiple Sclerosis Trial (Placebo, BIIB061, Interferon-beta1)

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Placebo
  • +3 more
  • (no location specified)
Mar 22, 2021